Browse Studies — Arctuva

Phase 4

A Single-arm Open-label Safety Study of SMOFlipid to Evaluate the Risk of Developing Essential Fatty Acid Deficiency (EFAD) and/or Parenteral Nutrition-associated Cholestasis (PNAC) in Pediatric Patients 1 Month to 17 Years of Age and in Adult Patients, Who Are Anticipated to Need 8 Weeks or Longer of Parenteral Nutrition Treatment

Evaluate the risk of developing EFAD and/or PNAC in adult and pediatric patients 1 month of age and older, who are anticipated to need 8 weeks or longer of par…

Malnutrition, ChildMalnutritionEssential Fatty Acid Deficiency (EFAD)+1 more

Estimated

~$10 – $7,500

Fresenius KabiNCT06049680

Phase 1

The Use of Near-Infrared Fluorescence Cholangiography With Indocyanine Green (ICG) in the Work Up of Neonatal Cholestasis

In infants that present with findings concerning for biliary atresia, along with other cholestatic work up which is standard, they will receive a one-time intr…

Biliary AtresiaKasaiCholestasis in Newborn+1 more

Estimated

~$10 – $6,250

University of Alabama at BirminghamNCT07250854

Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

The objective of this 5-year, prospective, observational cohort study is to evaluate the long-term safety and clinical outcomes of patients with Alagille syndr…

Alagille SyndromeProgressive Familial Intrahepatic Cholestasis

Estimated

~$10 – $1,050

Mirum Pharmaceuticals, Inc.NCT06193928